In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck buys Sirna for $1.1bn

Executive Summary

Merck & Co. has agreed to pay $13 per share for all of RNAi-based drug developer Sirna's outstanding equity (a 95% premium to Sirna's market average 10 days prior to the announcement of the deal), valuing the acquisition at approximately $1.1bn, or about 225 times Sirna's 2005 sales.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register